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Guest Editorial
Appropriate Use of Clopidogrel
CYRUS R KUMANA, BERNARD MAN-YUNG CHEUNG, IJ LAUDER*
From Department of Medicine and Department of Statistics & Acturial Science*, The University of Hong Kong,
Queen Mary Hospital, Hong Kong

Clopidogrel (Plavix®) is an orally administered
pro-drug, whose pharmacology and therapeutic role has
been extensively reviewed in recent publications.1-5 In
essence, it results in selective and irreversible
antagonism of ADP-induced platelet aggregation. Such
aggregation normally results in the surface expression
of platelet glycoprotein (GP) IIb/IIIa receptors, which
facilitate fibrinogen binding as well as consequential
further platelet aggregation – the final common pathway
of vascular occlusion. Specific cytochrome P450 enzymes
are thought to generate the responsible active metabolite
(believed to persist transiently). However, dosage
adjustment is not recommended in hepatic impairment
(unless severe) and drug-drug interactions and coadministration with meals are believed to be unimportant.
Based on clinical trials of outcome, several orally
administered anti-platelet drugs have proven efficacy
(mainly for secondary prevention) in the context of
coronary events, ischaemic strokes and peripheral
vascular disease. These include: (1) aspirin, (2)
dipyridamole (Persantin), (3) ticlopidine (Ticlid), and
(4) clopidogrel (Plavix) all of which have important
adverse effects.6,7 Dipyridamole gives rise to headaches,
postural lightheadness, and gastrointestinal symptoms
(mainly diarrhea & nausea). The relatively common
adverse effects of ticlopidine (neutropenia,
thrombocytopenia, hepatitis and diarrhea) pose a
problem. With clopidogrel, adverse effects are
comparable to aspirin and certainly less frequent and
less severe than with ticlopidine. However, it too has
been linked to thrombotic thrombocytopenic purpura
(even resulting in death).8 Moreover, clopidogrel's long
term safety has not been established, nor are the risks
known among ethnic groups (including the Chinese) that

Opinions expressed are views of the authors and not necessarily
the view of the editorial board or the Hong Kong College of
Cardiology.
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are believed to be more prone to bleeding.
Only a few of the relevant clinical trials have
compared different anti-platelet drug treatment
intervention regimes to each other with respect to
outcomes. In the multi-centre CAPRIE (Clopidogrel
v Aspirin in Patients at Risk of Ischaemic Events)
double blind randomised controlled trial, clopidogrel or
aspirin (both 75 mg/day) were given to 19,185
atherosclerotic patients. 9 The protocol entailed
randomisation to three groups viz: Stroke, MI &
Peripheral arterial disease (PAD), and follow up for 1-3
years. The ensuing results are outlined below (Table 1).

Table 1. Primary outcome (myocardial infarction,
ischaemic stroke or vascular death)
Clopidogrel
Placebo

Event ensued
939
1021

No event
8614
8846

Total
9553
9546

The relative risk reduction (RRR) was 8.7%
(adjusted) with a 95% CI of 0.3-16.5%; P<0.05. The
more meaningful absolute risk reduction (ARR)
amounted to 0.86% over an average of 1.91 years. The
corresponding number needed to treat (NNT) to prevent
one patient experiencing an adverse outcome event over
that period was 115 (95% CIs 57-∞), which is equivalent
to an NNT/year of 220. Unexpectedly the benefit was
largely confined to patients with prior peripheral arterial
disease and stroke.
That drugs such as clopidogrel, which inhibit ADP
induced platelet aggregation may complement the
antiplatelet activity of aspirin (a cyclo-oxygenase
inhibitor) without unduly compromising safety, has
kindled interest in using them in combination. In the
multi-centre CURE (Clopidogrel in Unstable angina to
prevent Recurrent Events) trial, 10,11 12,562 patients
taking aspirin (75-325 mg/day) ± heparin, β-blockers,
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statins or calcium channel blockers – were randomised
to treatment with clopidogrel (75 mg/day) or placebo
for 3-12 (mean of 9) months. The RRR (for
cardiovascular death, non-fatal stroke or MI) was 20%
(adjusted) with a 95% CIs of 10-28%. The corresponding
NNT was 47 or 35/year. Evidently, the relative risk (RR)
of major bleeding was 1.38% (95% CIs 1.13-1.67), there
being one such additional episode for every 99 patients
treated with clopidogrel and aspirin (as opposed to
aspirin alone) over this period of time (or 74/year).
However, there was no excess in bleeds causing fatality,
strokes or need for surgical intervention. Notably, for
many of the patients undergoing revascularisation
procedures, study medication was temporarily
interrupted or given as open label therapy. In the overall
analysis, it was estimated that for every 1000 patients
treated for 9 months, 28 major events would be
prevented at a cost of 3 patients having life-threatening
bleeds and 3 more requiring transfusions.12
In 2001, clopidogrel was among the Hong Kong
Hospital Authority's top 20 items of expenditure on
pharmaceuticals, having increased in popularity
dramatically over the last year. Compared to aspirin,
currently it is many orders of magnitude more expensive.
Thus, substituting clopidogrel for aspirin, treatment of
220 patients for 1 year would be expected to prevent 1
of them from suffering an ischaemic event, but
depending on which formulation was replaced corresponding drug costs could increase by between 46
to 205 fold (Table 2). In mitigation, use of clopidogrel
may involve cost-savings in terms of slightly reduced
numbers of patients having revascularisation procedures
and the associated use of much more expensive drugs
(GP IIb/IIIa receptor blockers).
Hitherto the conventional indications for
prescribing clopidogrel were mainly confined to: (1)

Table 2. Drug acquisition costs
Drug
Clopidegrel
Ticlopidine
Dipyridamole

Typical dosage/day
75 mg
250 mg
25 mg
75 mg

Aspirins
Asprin
Dispersable aspirin
Cartia
SR Cardiprin

2

80 mg
300 mg
100 mg
100 mg

HK$ (Nov 2001)
12.30
7.25
0.09
0.20
0.06
0.27
0.23
0.18

cover (together with aspirin) for patients undergoing
angioplasty and/or stenting procedures, and (2) as a
substitute for aspirin for individuals in whom the latter
drug was contraindicated or poorly tolerated. If the daily
cost of clopidogrel treatment (currently up to 205 fold
that of aspirin) is not an issue, it may also be reasonable
to use it: (3) instead of aspirin in all ischaemic
cardiovascular disease states, and (4) in combination
with aspirin for patients with unstable angina. However,
the long-term safety of this agent is not known.
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The Long-term Clinical Prognosis in Patients with Anterior Wall and
Non-anterior Wall Acute Myocardial Infarction Referred to Primary
Percutaneous Transluminal Coronary Angioplasty
MINGZHONG ZHAO, DAYI HU, TIANCHANG LI, SANQING JIA, MING YANG, YUYUN XU
From Department of Cardiology, People's Hospital, Beijing University, Beijing 100044, China
ZHAO ET AL.: The Long-term Clinical Prognosis in Patients with Anterior Wall and Non-anterior Wall Acute
Myocardial Infarction Referred to Primary Percutaneous Transluminal Coronary Angioplasty. Objective: To
investigate the long-term clinical prognosis in patients with anterior wall acute myocardial infarction (AW-AMI)
and non AW-AMI (NAW-AMI) referred to primary percutaneous transluminal coronary angioplasty (P-PTCA).
Methods: 287 patients with AMI who underwent P-PTCA were divided into AW-AMI group (142 cases) and NAWAMI group (145 cases) according to different sites of AMI. The baseline characteristics and coronary artery lesions
of patients were analysed. The primary end points were in-hospital mortality and the major cardiovascular events
(MACE) during a mean 17.3±9.8 months follow-up including the occurrences of non-fatal myocardial infarction,
non-fatal congestive heart failure, revascularization of target vessels and overall cardiac-related death. Results:
The peak values of CK and CK-MB were significantly higher (3533±2888 U/L vs 2322±1638 U/L, 158±197 U/L vs
95±64 U/L, all P<0.01), and left ventricular ejection fraction decreased (0.55±0.13 vs 0.61±0.12, P<0.05) and inhospital mortality increased significantly (4.1% vs 0, P<0.05) in AW-AMI group than in NAW-AMI group. At a
follow-up of mean 17.3±9.8 months, the incidences of non-fatal heart failure, in-hospital mortality, total cardiacrelated mortality and combined end points in AW-AMI group increased significantly than those in NAW-AMI group
(all P<0.05). Multivariate analysis revealed that anterior location of myocardial infarction and proximal left anterior
descending (LAD) coronary artery lesion were associated with the occurrence of cardiac-related death in patients
with AMI after procedure of PTCA (all P<0.05). Conclusions: The present study shows that anterior location of
myocardial infarction is associated with a higher incidence of MACE. The long-term clinical outcomes are poorer in
patients with AW-AMI than NAW-AMI referred to P-PTCA. (J HK Coll Cardiol 2002;10:3-6)
Acute myocardial infarction, angioplasty, percutaneous coronary, prognosis, transluminal
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Introduction
During the treatment of acute myocardial
infarction (AMI), early and effective recanalization of
infarct-related artery (IRA) is a very important strategy.
Primary percutaneous transluminal coronary
angioplasty (P-PTCA) or intracoronary stenting can
restore immediate TIMI 3 coronary flow of IRA. A few
reports showed the advantages of P-PTCA over
intravenous thrombolysis in the treatment of AMI. But,
the different sites of myocardial infarction might affect
the patients' clinical outcomes. The risk of patients with
anterior wall AMI (AW-AMI) was higher than that of
patients with non-anterior wall AMI (NAW-AMI)
because of their greater myocardial infarction sizes.1 In
the present study, we investigated the effect of P-PTCA
on the long-term clinical outcomes in patients with AWAMI and NAW-AMI.

included 142 cases (male:110 cases and female:32
cases) and the latter group included 145 cases (male:
103 cases and female:42 cases).

Angiography and PTCA
AMI patients were sent directly to catheterization
laboratory from Emergency Department. At first, CAG
was performed with Judkins method, then primary
PTCA or intracoronary stenting was decided according
to the characteristics of coronary artery disease.
Generally, we usually intervened with IRA during
emergency procedure.

Follow-up
Patients were followed up within 1 to 41 months
(a mean 17.3±9.8 months) for in-hospital mortality and
major cardiovascular events (MACE), which included
incidences of non-fatal myocardial infarction, non-fatal
heart failure, need for target vessel revascularization
(TVR) and total cardiac mortality.

Methods
Statistical Analysis
Patient Population
From January 1997 to December 2000, a total of
287 patients had taken emergency coronary artery
angiography (CAG) at our hospital with AMI and
suitable coronary anatomy for P-PTCA. The eligibility
criteria of P-PTCA were documented by the following:
(1) Persistent chest pain ≥30 min, with no relief by
nitrates; (2) ECG showing 1 mm ST segment elevation
in two contiguous limb leads or 2 mm ST segment
elevation in two contiguous precordial leads; (3) Fewer
than 12 hours from onset of symptoms; (4) AMI patients
with recurrent ischemic symptoms or persistent ST
segment elevation or CAG showing TIMI 0-II flow at
90 min after thrombolysis should undergo rescue PTCA.
For patients meeting above criteria, written informed
consents were obtained before they underwent PTCA
in the catheterization laboratory.
According to the presentation of electrocardiogram (ECG), AMI patients were divided into AWAMI and NAW-AMI groups. The former group
4

Continuous variables are expressed as mean±s;
discrete variables are expressed as percentages.
Differences between two groups were evaluated with
the student t test or χ2 test. The logistic regression
analysis was used to investigate the changes of risk
factors of cardiac death.

Results
Baseline Clinical and Angiographic
Characteristics (Table 1)
The results showed the percentages of patients
with angina before AMI or with Killip class II-IV, and
the peak values of CK or CK-MB were higher in AWAMI group than in NAW-AMI group (P<0.01).
Angiogram indicated that left anterior descending (LAD)
was the dominant IRA of patients with AW-AMI and
right coronary artery (RCA) was the dominant IRA of
patients with NAW-AMI.
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Discussion

The Results of Follow-up (MACE)
Stent was implanted in 91.6% and 86.9% of AWAMI and NAW-AMI patients respectively (P>0.05). Out
of 287 patients, 122 patients with AW-AMI and 117
patients with NAW-AMI were followed up. The
incidences of non-fatal heart failure, in-hospital
mortality, total cardiac death and combined end points
were significantly higher in the AW-AMI group than in
the NAW-AMI group (Table 2).

The Effect of IRA on Cardiac Death Rate (Table 3)
The mortality rate was higher in patients whose
IRA were left main trunk (LMT) than those whose IRA
were LAD, LCX or RCA. Proximal and non-proximal
lesions in IRA were identified according to the different
sites of coronary occlusion.2 Compared with patients
with non-proximal IRA lesions, the cardiac mortality
was higher in patients with proximal IRA lesions in LAD
(P<0.05).
Logistic regression analysis revealed that
myocardial infarction sites (anterior wall) and proximal
LAD lesion were associated with the occurrence of
cardiac-related death in patients with AMI after PTCA
procedure (all P<0.05).

This report described that the enzyme leak, the
Killip Class and left ventricular ejection were poorer in
patients with AW-AMI than NAW-AMI. More patients
with angina before AMI were presented in the AW-AMI
group. The increased risk of patients with anterior wall
AMI was associated with greater myocardial necrosis,
as well as larger infarct expansion, which resulted in
aneurysm formation, heart failure, mural thrombus
formation and myocardial rupture.3-5 CAG showed no
difference between the 2 groups besides IRA. LAD was
the dominant IRA in AW-AMI group, and RCA was
the dominant IRA in NAW-AMI group. It was reported
that AMI patients by occlusion of LAD had a higher
risk and more importantly clinical significance than
those by occlusion of LCX or RCA.6
The follow up data in this study showed that
although there was no significant difference in rates of
non-fatal myocardial infarction and TVR between the 2
groups, the incidences of non-fatal heart failure, inhospital mortality and total cardiac mortality increased
significantly in the AW-AMI group. The combined end
point event was also higher in the AW-AMI group than

Table 1. Baseline clinical and angiographic characteristics
Characteristics
Age
Hypertension
Hyperlipideremia
Diabetes
Smoking
Angina before AMI
Killip class II-IV
Duration from onset of symptom to reperfusion (min)
Rescue-PTCA
CK (U/L)
CK-MB (U/L)
LVEF
Single vessel disease
Multivessel disease
LM
Infarct-related artery (IRA)
LAD
LCX
RCA
LM

AW-AMI group (142)
63.2±8.9
35.9 (51/142)
26.8 (38/142)
11.3 (16/142)
38.0 (54/142)
59.9** (85/142)
28.8** (41/142)
251±154
11.3 (16/142)
3533±2888**
158±197**
0.55±0.13*
52.8 (75/142)
47.2 (67/142)
6.3 (9/142)

NAW-AMI group (145)
62.1±9.5
29.0 (42/145)
22.1 (32/145)
11.0 (16/145)
45.5 (66/145)
35.2 (51/145)
10.0 (15/145)
268±141
9.0 (13/145)
2322±1638
95±64
0.61±0.12
41.4 (60/145)
58.6 (85/145)
5.5 (8/145)

95.8** (136/142)
0**
1.4** (2/142)
2.8 (4/142)

2.8 (4/145)
20.7 (30/145)
76.5 (111/145)
0

LVEF, left ventricular ejection fraction; LM, left main; LAD, left anterior descending
*P<0.05, **P<0.01, patients with AW-AMI versus with NAW-AMI
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Table 2. The incidence of MACE in the two groups
MACE

AW-AMI (n=122)
case
%
2
1.6
18
14.8*
9
7.4
5
4.1*
8
6.6*
37
30.3*

Non-fatal myocardial infarction
Non-fatal heart failure
Target vessel revascularization
In-hospital mortality
Total cardiac death rate
Combine end points

NAW-AMI (n=117)
cases
%
1
0.9
8
6.8
10
8.6
0
0
2
1.7
21
18.0

*P<0.05, patients with AW-AMI versus with NAW-AMI

Table 3. The effect of IRA on cardiac death rate
IRA

Cases

LAD
proximal
non-proximal
LCX
proximal
non-proximal
RCA
proximal
non-proximal
LM
proximal
non-proximal

112
54
58
30

Cardiac mortality
cases
%
7
6.3*
6
11.1c
1
1.7
0**

References

21
9
93
57
36
4
1
3

2
1
1
1
1
0

2.2**
1.8
2.8
25.0
100

*P<0.05,**P<0.01, compared with patients whose IRA are LM;
cP<0.05, compared with non-proximal at the same vessel

the NAW-AMI group. Furthermore, our study also
showed the cardiac mortality rate was higher in patients
whose IRA was LMT or proximal in LAD compared
with other subgroups, but it should be further studied
due to limited cases. The present study indicated that
patients with AW-AMI was a high risk population, which
was identical to the results that Zijlstra reported.7 The
patients with AW-AMI were likely to have a greater
likelihood of a cardiac event at follow-up than NAWAMI. 8 The multivariate analysis revealed that
myocardial infarction sites (anterior wall) and proximal
LAD lesion were associated with the occurrence of
cardiac-related death in patients with AMI after the
PTCA procedure.

6

Our results showed that anterior location of
myocardial infarction was associated with a higher
incidence of MACE. The long-term clinical outcomes
were poorer in patients with AW-AMI than NAW-AMI
referred to P-PTCA.
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Syncope in Children in Hong Kong
GEOFFREY CHI-FUNG MOK, RITA YN-TZ SUNG
From Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
MOK and SUNG: Syncope in Children in Hong Kong. Objectives: Syncope is a common event in children. The
objective of this study was to review the aetiologies and their relative frequencies in the paediatric patients in a
general hospital in Hong Kong. Methods: This is a retrospective study of paediatric patients admitted to our hospital
between 1987 and 1996 with a presenting complaint of syncope. Their hospital notes were retrieved and reviewed.
The syncopal event and the circumstances together with the clinical assessment as well as the subsequent investigations
were analyzed in order to establish the respective aetiology for syncope. Results: Altogether 146 patients were
included in the study. The mean age was 10.4 years. Vasovagal syncope accounted for 54.1% of patients presented
with syncope. Seizure disorder accounted for 25.3%, while cardiac cause accounted for another 3 patients
(2.1%) with 2 patients having paroxysmal supraventricular tachycardia and 1 patient having frequent hypoxic spells
due to complex cyanotic heart disease. In 13.7% of patients, the cause of syncope was unknown. One patient belonging
to the seizure group died with autopsy finding revealing diffuse glioma at frontal region. Conclusions: Syncope is a
common presentation in the paediatric population and vasovagal syncope accounts for over half of the cases. Although
most cases of syncope are benign, it is important not to miss those cases in whom a life-threatening condition is
present. (J HK Coll Cardiol 2002;10:7-10)
Aetiology, children, syncope, vasovagal syncope
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Introduction
Syncope is a common presentation in the
paediatric population. The reported incidence of
paediatric syncopal episodes which received medical
attention was 71.9-125.8 per 100 000 population. 1
However, the actual incidence of paediatric syncope is
not known due to the lack of large-scale populationbased study in children. It has been estimated that as
many as 15% of children and adolescents experienced
at least one episode of syncope prior to the end of
adolescence.2
There are many causes of syncope. The most
common one is vasovagal or neurally mediated syncope,
which accounts for as much as 50% of the cases of
syncope in children.3-6 Neurally mediated syncope is
presumably due to relative hypovolaemia leading to
vigorous contraction of the heart, thus causing
stimulation of C-fibres and sympathetic withdrawal.7 Its
clinical course is usually benign. However, it is
important to exclude the minority of cases which have
a more serious and treatable cause of syncope, such as
epilepsy or underlying cardiac abnormality.
The objectives of this study were to review the
aetiologies and their relative frequencies in the paediatric
patients in a general hospital in Hong Kong.

Methods
This retrospective study included paediatric
patients admitted between 1987 and 1996 with a
presenting complaint of syncope who were identified
from our department audit database.8 Their hospital notes
were retrieved and reviewed. Patients who were already
known to have history of seizure attack or history of
arrhythmia were not included in the study. Syncope is
defined as the sudden, temporary and complete loss of
consciousness with loss of postural tone and with
spontaneous recovery.
Demographic information including the age at
presentation and sex of the patient was noted. Clinical
history was thoroughly reviewed with regards to the
detailed description of the syncopal event and the
circumstances under which syncope occurred. The
investigation results were noted, with particular
reference to the types of the blood tests performed,
electrocardiography, and other more specific

8

investigations including echocardiography,
electroencephalography, Holter monitor as well as brain
imaging. The cause of syncope was established based
on the review of the clinical presentation as well as the
relevant investigation results.
Diagnostic criteria for inclusion of cases in
different categories were defined as below. Vasovagal
syncope was defined as syncope that was preceded by
periods of prolonged upright posture followed by
prodromal symptoms of dizziness and diaphoresis prior
to the syncopal event. Triggering factors such as
emotional and stressful situations may be present.
Seizure disorder was diagnosed when the electroencephalogram showed epileptiform discharge or when
the patient developed clinical seizure subsequently.
Cardiac cause of syncope was diagnosed when there was
history of heart disease that was known to predispose to
syncope or when there were abnormalities detected on
electrocardiogram or echocardiogram that could account
for the syncope.

Results
Altogether 146 patients were included in the study
over the 10-year period from 1987 to 1996. There were
a total of 68 males and 78 females. The age ranged from
3 to 15 years old with a mean (±SD) age of 10.4±3.0
years. The results were shown in Table 1.
The majority of patients underwent the basic
investigation for the causes of syncope including
complete blood count, blood sugar, serum electrolytes
level, electrocardiogram and electroencephalogram.
Other more specific tests include echocardiogram,
Holter monitor, electrophysiological study and
computed tomography of the brain and the decision to
use these depended on the individual clinical

Table 1. Causes of syncope
Vasovagal
Seizure
Cardiac
Psychological
Others
Unknown
Total

January 2002

Number
79 (54.1%)
37 (25.3%)
3 (2.1%)
2 (1.4%)
5 (3.4%)
20 (13.7%)
146

Male
37 (54.4%)
24 (35.3%)
0
0
0
7 (10.3%)
68

Female
42 (53.8%)
13 (16.7%)
3 (3.8%)
2 (2.6%)
5 (6.4%)
13 (16.7%)
78
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presentation and indication. The relative frequencies of
the investigations performed were shown in Table 2.
Over half of the study population were classified
as having vasovagal syncope (54.1%). Seizure disorder
ranked the second important group among the causes of
syncope (25.3%). Psychological cause of syncope, such
as hysteria, consisted of 1.4%. Cardiovascular cause of
syncope accounted for 3 cases (2.1%) of the study
population. Among the 3 patients, 1 patient had
congenital complex cyanotic heart disease and had
repeated hypoxic spells. Two other patients had
paroxysmal supraventricular tachycardia. Other
miscellaneous causes of syncope accounted for 3.4% of
the study group and this included 2 patients with
vestibular disorder, 2 patients with upper respiratory tract
infection who were prescribed cough mixture and
1 patient with drug overdose. In 13.7% of the study
population, no aetiology of the causes of syncope could
be identified.
One patient in the study group subsequently died.
The patient was a 14-year-old girl who initially presented
with syncope. Her electroencephalogram showed
abnormal sharp waves and was diagnosed as having
epilepsy. This patient did not have a computed
tomography of the brain performed before her second
admission. She presented as status epilepticus two
months afterwards and died within few hours after
admission. She was found to have diffuse glioma at the
frontal region at autopsy.

Discussion
There were a few published series describing the
causes of syncope in childhood. Our study showed that
vasovagal syncope accounts for over 50% of syncope
in our paediatric population. This figure is consistent
with other published data shown in Table 3.
Vasovagal syncope or neurally mediated syncope
involving altered systemic vascular tone,9 is a diagnosis
mainly made based on the clinical history. However,
not every patient with vasovagal syncope would present
with the typical clinical features, thus occasionally
making vasovagal syncope difficult to diagnose.
Recently, the upright tilt testing has been increasingly
used both as a diagnostic aid as well as a means to
evaluate the various therapeutic measures for vasovagal
syncope, but different studies have shown variable
specificity, sensitivity and reproducibility which may
be a result of the absence of a unified study protocol.10,11
However, it is still considered to be a useful test in some
patients with vasovagal syncope in whom the clinical
presentation is less typical and a positive upright tilt
test may help to establish the diagnosis. In addition, a
positive tilt test in children was also found to be
predictive of increased incidence of recurrent rate of
syncope compared with those with negative tilt test.12
Cardiac cause of syncope accounts for only a
small percentage of the study population when compared
with Özme et al's report.5 This may be due to the fact

Table 2. The relative frequencies of investigations performed on patients presenting as syncope
Investigation
Complete blood count
Serum Electrolytes
Serum Glucose
Electrocardiography
Electroencephalogram
Computed Tomography of Brain

Number of positive tests/Number of patients tested
0/111
1/108
1/113
3/76
11/59
2/5

% positive
0
0.9
0.9
3.9
18.6
40

Table 3. Aetiologies of syncope in other published series
Number of patients
Vasovagal
Seizure
Cardiac
Migraine
Others
Unknown
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McHarg et al (1997)
108
75%
8%
6%
11%
0
0
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Özme et al (1993)
80
33%
11%
27.5%
0
1%
27.5%
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that the study patients were from general paediatric
wards rather than a cardiac centre. Our results are more
comparable to a population-based study published by
Driscoll et al,1 which described that only 6% of the
paediatric syncope was attributed to a pre-existing
cardiac aetiology. Nonetheless, it is of utmost
importance to look for any evidence of cardiac causes
of syncope as they are potentially life-threatening.
Attention needs to be paid to any possibility of
arrhythmia and left ventricular outflow tract obstruction,
and necessary investigations including Holter
monitoring, stress electrocardiography and echocardiography should be performed if cardiac cause of
syncope is suspected. 13 Electrocardiograms provide
many valuable information as arrhythmia may be
demonstrated, and the practice of measuring the QTC
interval is important as this may reveal the diagnosis of
long QT syndrome as the cause of syncope.
It has always been suggested that the yield of a
significant abnormality is relatively low if every child
presenting with syncope were to undergo the whole
series of comprehensive investigation and it would not
be cost-effective as well. This statement is best
exemplified in our study which showed that the basic
investigations which were frequently included as part
of the diagnostic workup for syncope had very low
diagnostic yield compared with the more selective
investigations such as electroencephalograms and
computed tomography of brain. However, there is
always the concern of the potential risk of missing the
diagnosis of a potential life-threatening cause of
syncope. It is thus important in the clinical assessment
to identify those individuals in which case the suspicion
of a potentially sinister cause of syncope is suspected,
such as patients with atypical history, patients with a
family history of sudden death, and patients with
abnormal clinical examination. These patients would
warrant further specific investigations accordingly for
the establishment of the respective diagnosis.
The study has its limitation. The true incidence
of syncope in children could not be estimated from the
study since not all children with syncope would present
to the hospital. In one emergency room series, syncope
accounts for <1% of all visits.3 In another study which
resembled a population-based study as the region was
served with a nearly uniform health care provider
service, it was found that only about 0.1% paediatric
patients came to seek medical attention for syncope.1

10

Clearly, it would be interesting to know if there is any
difference in the relative frequencies in the various
causes of syncope in the general paediatric population
compared with those who present themselves to
hospitals. Another limitation is related to the
retrospective nature of the study, in which the diagnostic
criteria used in this study were not prospectively defined.
Therefore, there may be potential error in their clinical
diagnosis and this may account for a relatively low
incidence of cardiac cause of syncope in the study
population.

Conclusions
Syncope is a common symptom in the paediatric
population and vasovagal syncope accounts for over half
of the patients presenting with syncope. Although most
cases of syncope are benign, it is essential not to miss
those cases in whom a life-threatening cause could be
identified, especially those patients with a cardiac cause
of syncope or central nervous system pathology.
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The Clinical Observation of Biventricular Pacing in Patients with
Congestive Heart Failure
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From Clinical Electrophysiology Laboratory, Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing,
China
HUA and CHEN: The Clinical Observation of Biventricular Pacing in Patients with Congestive Heart Failure.
Congestive heart failure is one of the leading health problems in medicine. Intraventricular conduction delay is
associated with contraction abnormalities, prolonged mitral regurgitation and a shortened left ventricular filling
time in patients with conduction defects and dilated cardiomyopathy. Biventricular pacing is a promising new strategy
for correcting the ventricular activation sequence and potentially improving myocardial function and clinical outcome
in patients with congestive heart failure. Uncontrolled and controlled studies have shown that biventricular pacing
could help to improve patients by at least one functional class, increases the 6-minute walk distance by 20-40%, and
improves quality of life (as assessed by the Minnesota living with heart failure questionnaire) by 20-50%. Left
ventricular lead implantation requires more time than implantation of traditional pacemaker leads. New technology
and techniques are likely to reduce the time required for implantation in the future. (J HK Coll Cardiol 2002;10:1116)
Biventricular pacing, clinical observation, congestive heart failure

Introduction
The aging of the population has made chronic
heart failure (CHF) an increasingly important health
problem. It is the leading medical cause of
hospitalization and its economic cost continues to
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increase. In recent years, pharmacological treatment
made considerable progress. Angiotensin converting
enzyme (ACE) inhibitors and B blockers have
significantly reduced mortality and morbidity in New
York Heart Association (NYHA) class II-IV patients,
while improving their quality of life. But that benefit is
probably not permanent and will be limited in time. A
variety of non-pharmacological approaches is available
to treat these refractory heart failure patients. Heart
transplant remains the best solution but can only be
applied to a restricted number of patients.
Intraventricular conduction delay is associated
with asynchronous ventricular contraction, even in
patients without heart failure. Contraction abnormalities,
prolonged mitral regurgitation and a shortened left
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ventricular filling time have also been documented in
patients with conduction defects and dilated
cardiomyopathy.1-4 Biventricular pacing is a promising
new strategy for correcting the ventricular activation
sequence and potentially improving myocardial function
and clinical outcome in patients with heart failure.5-8
Although large controlled clinical trials of biventricular
pacing have yet to be completed, currently available data
suggest that patients with advanced heart failure and
ventricular conduction abnormalities may benefit from
such therapy.

Intraventricular Conduction Delay
and Biventricular Pacing
Wide QRS are frequently observed in patients
with chronic heart failure associated with left ventricular
(LV) systolic dysfunction. Some studies revealed a
prevalence of intraventricular conduction delay (as
defined by QRS duration >120 ms) in chronic heart
failure patients, estimation at 27-53%.9 These conduction
abnormalities - intraventricular conduction delay in
particular is considered to be an independently predictive
factor of mortality. Thus in the Vesnarinone Trial
(VEST) study,10 the 6 years mortality rate in patients
with chronic heart failure with altered LV function (LV
ejection fraction <40%) was significantly higher in
patients whose QRS duration exceeded 110 ms (65%)
than in those where it did not (40%), regardless of the
degree of LV impairment.
In addition, these conduction disorders have
deleterious effects both on systolic function and on LV
filling, and they can induce or enhance mitral
"functional" regurgitation. Xiao and colleagues 11
demonstrated, in dilated cardiomyopathy (DCM)
patients, that the presence of a left bundle branch block
(LBBB) was associated with a more than 80% increase
in LV pre-ejection contraction time and 60% increase
in LV relaxation time; there was also a negative
correlation between the QRS duration and the +dp/dt.
So, the wider the QRS, the lower the contractility. In
the same studies, analyzing the parameters of LV
diastolic function revealed that the LV filling time was
significantly reduced (by nearly 40%) in DCM patients
in the presence of LBBB or a significant prolongation
of the PR interval (>200 ms). In parallel, the quality of
atrial contribution to LV filling was impaired, as

12

reflected on transmitral Doppler by a single phase flow
linked to E wave and A wave superimposition. Lastly,
in patients with LV systolic dysfunction, the presence
of an LBBB or prolonged PR interval is associated with
an increase in the duration of mitral regurgitation.
Incidentally, the presence of an LV-left atrial diastolic
gradient-frequently found in patients with DCM and
atrioventricular conduction disorders which can be the
origin of diastolic mitral regurgitation.
The aim of multisite biventricular pacing is to
correct not only the atrioventricular asynchrony but also
the nonuniformity of ventricular activation, contraction
and relaxation sequences. It is proposed primarily for
patients with drug refractory heart failure with LV
systolic dysfunction and wide QRS complex. In 1994
Cazeau et al12 from France reported the remarkable
benefit of biventricular pacing in a patient with drugrefractory CHF due to dilated cardiomyopathy, and left
bundle-branch block (QRS=200 ms). The left ventricle
(LV) and right ventricle (RV) were paced simultaneously
to achieve a more physiologic depolarization sequence.
Since this report, a substantial number of short-term
studies have shown that biventricular pacing improves
haemodynamics in CHF patients with severe left
ventricular systolic dysfunction and major left sided
intraventricular conduction disorders.6,7,13,15,16 A longer
spontaneous QRS complex may be predictive of a
greater positive response to pacing. Intraventricular
conduction delays cause an inefficient dysynchronous
pattern of left ventricular activation with segments
contracting at different times. The rationale of
biventricular pacing is to improve the sequence of
electrical activation (resynchronization) and create a
more coordinated and efficient left ventricular
contraction. Resynchronization may also reduce
functional mitral regurgitation. 14-16 Reversal of left
ventricular remodeling by synchronous biventricular
pacing in heart failure was reported.17
Patients with chronic atrial fibrillation may also
benefit. In this instance, continual biventricular pacing
often requires radiofrequency ablation of the Atrialventricular (AV) junction to ensure control of ventricular
depolarization by the pacemaker.18 Optimized AV delay
played an important role in improvement of
hamodynomics particularly in patients accompanied by
atrioventricular conduction delay. Shortening AV
interval could reduce presystolic regurgitation and
improve filling pattern of the left ventricle.19
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Left Ventricular Pacing Technique
To achieve biventricular pacing, left ventricular
lead placement is the most important part. The cardiac
venous structures differ among individual patients, with
wide variations in the location and size of the coronary
sinus and its side branches. Consequently, adequate
visualization of the venous anatomy is very important
in transvenous left ventricular lead placement. The
venous phase of the coronary angiogram sufficiently
outlines the coronary sinus ostium and a number of its
branches in about 20% of patients. Selective coronary sinus
catheterization from the subclavian route undoubtedly
provides better visualization of potential sites for lead
placement. The use of an occlusive balloon enhances
the quality of the images. AP, RAO, and LAO views of
the coronary sinus will help in guiding the leads, and a
knowledge of the position, angulations, and size of the
side branches will assist in lead selection and placement.
The lead most commonly used for left ventricular
pacing is the attain LV model 2187, a unipolar,
polyurethane lead, available in 65 cm or 75 cm length,
with a curved distal body and a soft tip. The tip can be
straightened using the stylet. Withdrawal of the stylet
alters the curve, allowing angulation of the lead to the
desired location. Recently, the new transvenous overthe-wire and side wire (Figure 1) left ventricular lead
system has been used in clinical practice.20,21 The left
ventricular lead is implanted via the subclavian vein and,

Figure 1. Side-wire left ventricular lead system
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ideally, placed in a vein in the posterolarteral or lateral
wall of the heart, where the sensed endocardial signals
occur late in the QRS complex. The right ventricular
lead is then placed at a site anatomically remote from
the left ventricular lead, with good electrical separation
and, preferably, early in the QRS complex.
Successful transvenous ventricular lead
implantation is defined as (1) a stable left ventricular
lead position, (2) satisfactory pacing thresholds and (3)
good electrical and anatomic separation of the right and
left ventricular leads. The clinical experience shows that
success rate for transvenous left ventricular lead
implantation was 84-93%.22,23 Left ventricular lead
implantation requires more time than implantation of
traditional pacemaker leads. New technology and
techniques are likely to reduce the time required for
implantation in the future.

Clinical Observation of
Biventricular Pacing
Results from uncontrolled studies suggest that
multisite pacing improves selected heart failure patients.
One of the largest of these is the InSync study.24,25 It
comprised 103 patients with severe heart failure of
mixed etiology. All patients had severe heart failure,
NYHA functional class III-IV, and a QRS duration of
at least 150 ms. Significant improvements by
biventricular pacing were seen in most patients after 12
months of pacing compared to baseline with regard to
NYHA class, 6-minute walk distance, and quality of
life. Moreover, pacing reduced the QRS duration
significantly and normalized the intraventricular delay
as an indication that ventricular resynchronization had
been achieved.
There are a number of randomized trials on the
efficacy and safety of biventricular pacing, the results
of some of them remain to be published (Figure 2). In
the Pacing Therapies for Congestive Heart Failure
(PATH CHF) trial,26 patients with severe heart failure
(120 ms) were included. After an extensive acute
invasive evaluation performed during implantation, the
patients were randomized during implantation, the
patients univentricular mode - that is, right or left
ventricular pacing only, no pacing, and biventricular
pacing. The study enrolment ended in 1998 and included
54 patients. Interim results indicate a 40% improvement
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in the 6-minute walk distance and a 50% improvement
in quality of life after 1 month of the best univentricular
mode cases constituted by left ventricular pacing, and
1 month of biventricular pacing.
The Multisite Stimulation in Cardiomyopathy
(MUSTIC) study22 involves 67 patients. Enrolment was
completed in June 1999. This study includes only NYHA
class III heart failure patients with a sinus rhythm, QRS
duration of at least 150 ms. The patients were randomized
in a single blind crossover fashion to 3 months each of
biventricular pacing or fixed rate ventricular pacing at
a rate of 40 beats per minute. The primary end points
are the 6-minute walk distance and maximal oxygen
uptake, with quality of life as a secondary end point.
The result shows that the mean distance walked in
6 minutes was 23% greater with active pacing, the
quality-of-life score improved by 32%, peak oxygen
uptake increased by 8%, hospitalizations were decreased
by two thirds, and active pacing was preferred by 85%
of the patients.
The Multicenter Insync Randomized Clinical
Evolution (MIRACLE) study23 is a large prospective,

PATH-CHF
Study with 2
Devices &
Epi LV
Leads Begins

1994

1995

Daubert, et al
Trial in 2 French
Centers Using Epi,
Then Transvenous
LV Leads

SCD-HeFT
N=2500
Std Rx vs.
Amiodarone vs. ICD

1996

1997

randomized, double-blind, controlled trial designed to
more definitively evaluated the clinical efficacy and
safety of cardiac resynchronization for heart failure.
Until July 2000, this study has being enrolled 370
patients with NYHA class III and IV systolic heart failure
and QRS durations of 130 ms or more. The primary end
points is defined the effects on functional status (quality
of life, NYHA class, 6-minute hall walk distance) at
6 months. The result was presented in the North American
Society of Pacing and Electrophysiology, 22nd Annual
Scientific Sessions (NASPE 2001). The success rate for
transvenous left ventricular lead was 93%. The 6-minute
walk distance was 350 meters in active pacing and 300
meters during control phase. The quality of life score
was improved 22%. The peak oxygen uptake was a trend
to increase but no significant difference (p=0.056).
Biventricular pacing is a promising treatment in
patients with severe heart failure with intraventricular
conduction disturbances. It helps to improve patients
by at least one functional class, increases the 6-minute
walk distance by 20-40%, increases the oxygen uptake
by 8-40%, and improves quality of life (as assessed by
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Figure 2. Clinical studies about resynchronization therapy.
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the Minnesota living with heart failure questionnaire)
by 20-50%. These figures are impressive. From
uncontrolled and controlled studies it is also clear that
not all patients respond to this treatment. Clinical,
electrical or echocardiographic predictors of response
to pacing are needed in view of the costs involved in
pacemaker implantation and follow up. The ultimate
success of the ambitious efforts to resynchronize cardiac
activity in CHF will depend on defining its real benefit
in a variety of circumstances by rigorous scientific
evaluation and the development of new technology or
further refinement of existing technology. For example,
adjusted RV-LV stimulation delay - rather than
simultaneous activation - may enhance the hemodynamic response. Left ventricular dual-site pacing
seems to improve haemodynamics compare to single
site left ventricular pacing. Implantable CardioverterDefibrillator (ICD) encompass the biventricular pacing
could reduce episodes of ventricular tachyarrthmias by
improve heart function in patients with intraventricular
conduction delay.27,28 Ongoing clinical studies (InSynchICD, CONTAKCD, COMPANION) will prove ICD
combine biventricular pacing could further improve the
quality of life and survivals.
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Update on the Treatment of Hypertension
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CHEUNG: Update on the Treatment of Hypertension. Despite recognition of the dangers of untreated and
uncontrolled hypertension, it is still widely and persistently under-treated in the community. Universal screening of
all adults for hypertension is essential, as the probability of hypertension in any randomly chosen person is
considerable, especially from middle age onwards. The level of blood pressure, the presence of other risk factors,
target organ damage and overt cardiovascular disease allow the physician to estimate the cardiovascular risk of a
patient. The urgency of treatment depends on the degree of risk. It is now believed that the control of hypertension is
the primary goal. This may necessitate changing the class of antihypertensive drug or using a combination of different
classes. The choice of drug class is also determined by co-morbidities. The control of blood pressure to the point of
normalisation of blood pressure is safe and beneficial, especially in diabetics. In patients with mild hypertension,
non-pharmacological treatment through lifestyle modification has a definite place. (J HK Coll Cardiol 2002;10:1720)
Antihypertensive drugs, blood pressure, cardiovascular diseases, hypertension

Update on Hypertension
The risks of untreated hypertension are well
known and well understood. Blood pressure has a direct
relation with the risk of stroke and myocardial infarction.
Hypertension may also lead to left ventricular
hypertrophy, heart failure and renal failure. Despite
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recognition of the dangers of untreated and uncontrolled
hypertension, it is still widely and persistently undertreated in the community. Many hypertensives remain
undiagnosed. Of those who have been diagnosed, many
of them are not on treatment. Of those who are on
treatment, many are not well controlled. This "rule of
halves" has been demonstrated in many countries around
the world, including even the United States. 1 As
hypertension is an asymptomatic disease, screening in
apparently healthy individuals is warranted. The
probability of hypertension in an individual in the
general population is around 20%; this increases to as
high as 50% in the elderly.2 Universal screening of all
adults for hypertension is essential, as the probability
of hypertension in any randomly chosen person is
considerable, especially from middle age onwards.
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Screening for hypertension in first degree relatives is
arguably mandatory in view of the clustering of
hypertension in families due to shared genetics and
environmental factors.
If high blood pressure is undesirable, we may ask
what is the ideal blood pressure for normal people and
what is the treatment target for hypertensives. We have
little definite information on the former but we now have
a partial answer for the latter. In the Hypertension
Optimal Treatment (HOT) Study, an achieved diastolic
blood pressure of 83 mmHg was associated with the
lowest incidence of cardiovascular events (Table 1).3
However, there was scarcely any difference whether the
target diastolic blood pressure was <80, <85 or <90 mmHg.
The results of HOT allow a dual interpretation; aggressive
blood pressure reduction is justifiable as there is no harm,
but cautious and cost-conscious prescribing is also
justified as there is little additional benefit from lowering
the diastolic blood pressure below 90 mmHg. Instead
of increasing the dose or adding on another drug if the
diastolic blood pressure is already below 90 mmHg, one
might consider addressing other modifiable risk factors.
There is one subgroup of hypertensives who should have
aggressive reduction of blood pressure; these are the
diabetics. In HOT and the UK Prospective Diabetes
Study (UKPDS),4 there were benefits in lowering the
blood pressure beyond 140/90 mmHg. A target blood
pressure of <130/85 mmHg is now recommended for
diabetics.5
There is increasing recognition that elevated
systolic blood pressure is of prognostic significance and
treatment of systolic hypertension is beneficial, even if
the diastolic blood pressure is normal as in isolated
systolic hypertension. In the latest guidelines, a systolic
blood pressure of 140 mmHg or above is considered
abnormal.1,5,7 However, a large proportion of the elderly
has a systolic blood pressure higher than this. Thus, a
large section of the elderly population is at risk from
the complications of hypertension and requires a
combination of lifestyle modifications and drug
treatment.
The role of other additional medications for
hypertensive patients is unclear. Aspirin was shown to
be beneficial in HOT in terms of reduction of cardiovascular events, but the incidence of gastrointestinal
bleeding is also increased, so the risks and benefits have
to be worked out for each patient. Antioxidants are less
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promising than they have appeared to be; the Heart
Outcome Prevention Evaluation (HOPE) did not show
any cardiovascular benefit associated with vitamin E
supplementation.6
The assessment of the overall cardiovascular risk
for each patient is the cornerstone in the latest World
Health Organisation (WHO) guidelines4 as well as the
British Hypertension Society guidelines 7 for the
management of hypertension. As hypertension is only
one of a number of risk factors for cardiovascular
disease, it is desirable to address all these risk factors
rather than to consider the level of blood pressure in
isolation. Hence, in the new paradigm, the level of blood
pressure, the presence of other risk factors, target organ
damage and overt cardiovascular disease allow the
physician to estimate the cardiovascular risk of a patient.
The urgency of treatment depends on the overall degree
of cardiovascular risk as well as the level of blood
pressure. This new mode of thinking, although initially
complicated, is an improvement on treating the blood
pressure with disregard of actual cardiovascular risk. A
pre-menopausal woman with mild hypertension, e.g.
150/100 mmHg, but no other risk factors has a very low
immediate risk of cardiovascular events and should
probably have lifestyle changes to lower blood pressure
as far as possible. The same level of blood pressure in a
60-year-old male smoker with multiple risk factors
requires treatment and aggressive modification of other
risk factors to lower the cardiovascular risk. However,
a major disadvantage of using cardiovascular risk in
treatment decisions is that it makes no distinction
between a cardiovascular event in the young and in the
elderly. In the very elderly, treatment might only prolong
life marginally whereas it is disastrous if a young person

Table 1. Recent major clinical trials
Trial objective
Optimal blood pressure target
Hypertension in diabetics
CCB vs. placebo
CCB vs. other drugs
ACEI vs. placebo
Comparing several drug
classes
Diet
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Name of Trial
HOT3
UKPDS4
Syst-Eur,10 Syst-China11
INSIGHT,13 NORDIL14
HOPE,6 PROGRESS18
STOP-2,12 ALLHAT17
DASH,19,20 TONE21
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has a debilitating stroke. It is therefore important to
consider the potential benefits of treatment as well as
the risks of no treatment.8
The relative merit of different classes of
antihypertensive drugs is always a controversial area,
not least because of commercial interests. The WHO,5
British7 and JNC-VI1 guidelines have all attempted to
address this issue. It is now believed that the control of
hypertension is the primary goal. This may necessitate
changing the class of antihypertensive drug or using a
combination of different classes. Following some
adverse findings about calcium channel blockers (CCBs)
mainly from case control studies,9 randomised controlled
trials such as Systolic Hypertension in Europe (SystEur),10 Systolic Hypertension in China (Syst-China),11
the Swedish Trial in Old Patients with Hypertension-2
(STOP-Hypertension-2),12 the International Nifedipine
GITS Study Intervention as a Goal in Hypertension
Treatment (INSIGHT) 13 and Nordic Diltiazem
(NORDIL) Study14 have shown that this drug class also
reduces cardiovascular events. This underlines the
paramount importance of blood pressure control.
However, two meta-analyses of hypertension trials have
recently been published with somewhat conflicting
conclusions regarding CCBs. One reported a
significantly higher risk of myocardial infarction and
heart failure associated with CCBs,15 whereas the other
regarded these differences to be of borderline
significance.16 In Asia, the incidence of stroke is higher
than that of myocardial infarction. As CCBs are effective
in lowering blood pressure and reducing the risk of
stroke, they have an important place in the formulary.
The merits of alpha-blockers are put in doubt by
the Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT), in which a higher
rate of cardiovascular events, mainly heart failure and
strokes, was observed in the alpha-blocker arm. 17
However, there was no difference in the primary
endpoint, which was the occurrence of fatal and nonfatal myocardial infarction. Alpha-blockers may not be
the first-line drug for the treatment of hypertension, but
they remain useful for the control of blood pressure,
especially in elderly male patients with prostatic
symptoms.
The latest guidelines have also incorporated
clinical trial evidence to support the use of certain classes
in certain situations. For example, a hypertensive with
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angina should receive beta-blockers. ACEIs have
emerged as an important drug class, preventing
cardiovascular events in those who are at risk, as shown
in the HOPE study.6 On the other hand, both the STOPHypertension-2 and the UKPDS failed to show that
ACEIs are superior to conventional antihypertensive
agents.
In the HOPE study, subjects randomised to
treatment with an ACEI had lower cardiovascular events
even if they were normotensive.6 It has been argued that
the degree of blood pressure lowering did not fully
explain the benefits observed. It was postulated that
ACEIs might have a protective effect beyond blood
pressure reduction. Interestingly, in the Perinodopril
pROtection aGainst Recurrent Stroke Study
(PROGRESS), a decrease in stroke rate was observed
in normotensive as well as hypertensive patients
randomised to treatment with an ACEI.18
The cost-effectiveness of antihypertensive
medications varies enormously because of the
tremendous differences in the price of drugs. At the same
time, the efficacies of antihypertensive drugs are
remarkably similar. Large clinical trials have shown that,
in terms of cardiovascular outcome, the newer classes
are not superior to beta-blockers and diuretics.12,13,17 In
patients at high risk from cardiovascular disease, use of
expensive medications may be acceptable. Yet, in
patients with mild hypertension and at low risk from
cardiovascular disease, cost-effectiveness should not be
ignored, especially in the public sector. Nevertheless,
patients respond differently to antihypertensive
medications and some may require newer and more
expensive medications to control their blood pressure
or to avoid side effects.
In the approach to treating patients with mild
hypertension, non-pharmacological treatment has a
definite place. Factors leading to hypertension in Hong
Kong include ageing, family history, obesity and
diabetes. The Dietary Approaches to Stop Hypertension
(DASH) study showed that a healthy diet rich in fruits
and vegetables and low in fat and sodium lowers blood
pressure. 19,20 The Trial of Non-pharmacologic
intervention in the Elderly (TONE) showed that weight
loss and reduction in salt intake resulted in decreased
blood pressure and need for antihypertensive
medications.21 We have also identified sodium intake
as a strong determinant of diastolic blood pressure.22
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Obesity and sodium intake are modifiable risk factors.
In patients with mild hypertension, lifestyle measures
may be sufficient to control blood pressure or at least
ameliorate it. For the whole population, universal
screening for hypertension and a healthier lifestyle are
likely to bring about the largest amount of benefit to the
greatest number of people with the minimum of risks.
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ECG Quiz
CHIU-SUN YUE, WAI-KWONG CHAN
From Division of Cardiology, Department of Medicine & Geriatrics, United Christian Hospital, Kowloon, Hong
Kong

A 90-year-old gentleman was referred to
Accident and Emergency Department (AED) by
community nurse because he complained of dizziness.
He has history of atrial fibrillation, congestive heart
failure and Parkinsonism on regular medical treatment.
At AED, a 12-lead ECG was done. What was the
diagnosis ? (see ECG attached)
1) a)
b)
c)
d)

Fast atrial fibrillation with aberrant conduction
Atrial flutter with 1:1 conduction
Non-sustained ventricular tachycardia
Tremor-induced ECG artifact

What would be your initial management for this
patient ? (His blood pressure was 119/89mmHg and he
was conscious)

2) a)
b)
c)
d)

Intravenous lignocaine
Intravenous ATP
Intravenous verapamil
Observe and repeat ECG later

Cardiologist was consulted for further
management because of suspected ventricular
tachycardia and dizziness. Physical examination
revealed the features of Parkinsonism. A 12-lead ECG
was repeated which showed atrial fibrillation and right
bundle branch block with tremulous isoelectric line.
Blood biochemistry was unremarkable. Echocardiogram
revealed satisfactory left ventricular function with mild
mitral, aortic and tricuspid regurgitation. He remained
stable after admission and was discharged home shortly
afterwards. The diagnosis in this patient was tremor-

Figure 1. 12-lead ECG done at Accident and Emergency Department
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induced ECG artifact mimicking ventricular tachycardia
due to underlying Parkinsonism with marked resting
tremor.

Answers
1) d) Tremor-induced ECG artifact
2) d) Observe and repeat ECG later

Discussion
This patient suffers from Parkinsonism for years
with history of frequent fall and marked resting tremor.
Tremor-induced ECG artifact was suspected at first
glance after admission because of the following reasons.
First, he was relatively asymptomatic and
hemodynamically stable apart from some non-specific
dizziness prior to admission. Second, distinct QRS
complexes were shown to be buried in the wide
amplitude repetitive electrical activity mimicking
ventricular tachycardia on careful inspection.1 Third,
judging from the cycle length of the wide amplitude
electrical activity, the frequency of the resting tremor
was estimated to be 3 to 4 Hz which correlated with
that seen in Parkinsonism. Fourth, the wide amplitude
electrical activity was more pronounced in the limb
leads. Fifth, the ECG was interpreted in the context of
the patient with history mentioned above. His previous
ECGs already revealed tremulous isoelectric line with
background atrial fibrillation and right bundle branch
block. Fortunately, no treatment was prescribed for the
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ECG artifact in this patient.
In daily clinical practice, electrocardiogram is a
common and useful investigation, especially for patients
presenting with cardiac problems. Physician should be
aware of common ECG artifacts, which can be caused
by skeletal muscle tremor, electrical interference from
the network or appliance and electrode movements.
ECG artifacts may make ECG interpretation difficult
or may cause incorrect ECG interpretation with
inappropriate subsequent management.
Knight et al. reported 12 artifacts simulating
monomorphic or polymorphic ventricular tachycardia.2
All those twelve patients underwent unnecessary
diagnostic or therapeutic interventions as a result of
ECG misdiagnosis, for example, cardiac catheterization,
electrophysiologic testing, intravenous lignocaine,
implantation of permanent pacemaker and implantable
cardioverter defibrillator. Moreover, the use of health
care resources was increased and inappropriate in those
cases.
In conclusion, when one interprets a wide QRS
complex ECG, tremor-induced ECG artifact should be
included in the differential diagnosis, especially if the
patient has relevant medical illness.
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